Dr. Markus Fido

Markus has more than 25 years of experience in pharmaceutical industry, with focusin vaccines, recombinant proteins, and immune therapeutics. He has profoundexpertise in regulatory aspects such as third-party audits, authority inspections andGMP guidelines.

He has a management consulting education and holds a doctorate degree in immunology/biochemistry from the Technical University of Graz, Austria. Markus started his carrier at a Novartis “Spin off” in Vienna in 2006, later on he has acquired the oncology division from Novartis and founded 2 Biotech companies, VelaLabs & Meridian Biopharmaceutics.

Besides serving as a CEO and formal Managing Director, Markus has also taken responsibilities as a Head of Regulatory Affairs within the Quality Operations team. Markus was previously Head Quality Control at Igeneon / Aphton Biopharma where he was responsible for all QC aspects of pre-clinical and clinical projects such as stability studies, specifications, method validation, and product release. Before he was Group Leader of Immunology and Product Development at Biomin GmbH, Head Biochemical Control at Baxter AG and Head Quality Operations at Octapharma AG.